EBAY
43
-2
TSN
38
-2
GIS
58
-2
EL
55
-3
CMCSA
55
-2
TJX
58
-3
NWL
35
-4
CMA
52
2
HUM
43
-4
AAP
27
3
AA
53
5
NUE
40
-3
ORCL
68
3
MRO
50
11
HRB
85
-2
MU
56
-3
AAL
50
2
LRCX
55
-6
ALLE
37
-4
CI
49
3
EBAY
43
-2
TSN
38
-2
GIS
58
-2
EL
55
-3
CMCSA
55
-2
TJX
58
-3
NWL
35
-4
CMA
52
2
HUM
43
-4
AAP
27
3
AA
53
5
NUE
40
-3
ORCL
68
3
MRO
50
11
HRB
85
-2
MU
56
-3
AAL
50
2
LRCX
55
-6
ALLE
37
-4
CI
49
3
Financhill
Back

Xtacy Therapeutics 10K Form

Sell
22

XTCY.CX
Xtacy Therapeutics

Last Price:
0.03
Seasonality Move:
2.91%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive XTCY.CX News And Ratings

See the #1 stock for the next 7 days that we like better than XTCY.CX

XTCY.CX Financial Statistics

Sales & Book Value

Annual Sales: $21.83K
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-0.01
Price / Book: 0

Profitability

EPS (TTM): -0.02000
Net Income (TTM): $-633.2K
Gross Margin: $19.54K
Return on Equity: 0%
Return on Assets: 0%

Xtacy Therapeutics Earnings Forecast

Key Xtacy Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 16 years for XTCY.CX is 89.51%.
  • The Selling, General & Administrative Expenses for XTCY.CX have been equal to 3,924.46% of Gross Profit Margin.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 16 years have been positive in 9 years.

Xtacy Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: CNSX
Current Symbol: XTCY.CX
Website: globalwellnessstrategies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

XTCY.CX Technical Analysis vs Fundamental Analysis

Sell
22
Xtacy Therapeutics (XTCY.CX) is a Sell

Is Xtacy Therapeutics a Buy or a Sell?